# OnCo record paper-nct03334617-nat-med-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct03334617-nat-med-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct03334617-nat-med-2024" ;
  schema:name "Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial"@en ;
  schema:description "Published report from the PD-L1 Containing Therapy trial registered as NCT03334617, in Nature Medicine (2024), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct03334617-nat-med-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41591-024-02808-y>, <https://pubmed.ncbi.nlm.nih.gov/38351187/>, <https://europepmc.org/article/MED/38351187>, <https://clinicaltrials.gov/study/NCT03334617> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1038/s41591-024-02808-y> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Besse B, Pons-Tostivint E, Park K, et al." ;
  onco:trials <https://onco.cc/trials/nct03334617/> ;
  onco:journals <https://onco.cc/journals/nature-medicine/> .